Publications by authors named "C Van Praet"
A comprehensive view of N-glycosylation as clinical biomarker in prostate cancer.
Biochim Biophys Acta Rev Cancer
February 2025
Alterations in the prostate cancer (PCa) N-glycome have gained attention as a potential biomarker. This comprehensive review explores the diversity of N-glycosylation patterns observed in PCa-related cell lines, tissue, serum and urine, focusing on prostate-specific antigen (PSA) and the total pool of glycoproteins. Within the context of PCa, altered N-glycosylation patterns are a mechanism of immune escape and a disruption in normal glycoprotein distribution and trafficking.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the outcomes of robot-assisted radical cystectomy (RARC) with intracorporeal orthotopic neobladder in women with bladder cancer, specifically focusing on functionality, cancer results, and complications.
- The research involved 146 female patients, revealing that about half underwent pelvic organ-preserving procedures, achieving overall daytime and nighttime continence rates of 54% and 53%.
- The findings concluded that RARC with orthotopic neobladder offers good functional outcomes, with pelvic organ preservation improving urinary continence while maintaining cancer safety.
Background: Muscle invasive bladder cancer (MIBC) treatment combines systemic therapy and radical cystectomy (RC) or local (chemo-)radiotherapy. Response to systemic therapy is an important outcome predictor but is difficult to assess pre-operatively.
Methods: We analyzed multiparametric MRI (mpMRI) in consecutive MIBC patients receiving cisplatin-based neo-adjuvant chemotherapy at our institution.
Article Synopsis
- *Diagnosing MSK can be challenging, especially when there is a concurrent renal mass, which might complicate the imaging results.
- *The report presents a rare case of Bellini duct carcinoma occurring in a patient with MSK, along with a review of related literature on this complex kidney disorder.
Article Synopsis
- The study investigates the use of a radioactive monoclonal antibody, [Zr]Zr-girentuximab, for non-invasive detection of clear-cell renal cell carcinoma in patients with renal masses.
- Conducted across 36 sites in nine countries, the phase 3 trial involved 332 enrolled patients with suspicious renal masses, who received the antibody followed by PET-CT imaging.
- The primary goals of the trial were to assess the sensitivity and specificity of the imaging technique using histopathological confirmation as the standard, with findings from 300 patients eventually analyzed.